Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals has registered the remaining 135,000 shares of its common stock to be issued under the 2026 Equity Incentive Plan. This registration is intended for employee equity compensation, following the company's 1-for-20 reverse stock split effected on August 20, 2026.…more
Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals is facing two putative securities class actions alleging material misstatements and omissions in its August 2025 IPO offering documents. Plaintiffs claim damages related to risks of stock-price manipulation and deficiencies in underwriter due diligence, and the company intends to defend itself vigorously.…more
Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals has regained compliance with the Nasdaq minimum bid price requirement following a 1-for-20 reverse stock split effective August 20, 2026. The company maintained a closing bid price of $1.00 or greater for 10 consecutive business days from August 20 to September 2, 2026, officially closing the compliance matter.…more
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Curanex Pharmaceuticals Trading Halt and Resumption
Trading of Curanex Pharmaceuticals shares was temporarily halted and subsequently resumed. This notice reflects standard market procedures and does not contain specific positive or negative corporate news.…more
●●●●●●●● ●●●●● ●●●●●●
Trading of Curanex Pharmaceuticals stock has been halted pending the release of material news. Investors should monitor upcoming announcements as they may impact the stock price significantly.…more
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.